文献速递贫血与红细胞疾病

基于BCL11A和HBS1L-MYB变异的遗传风险评分可预测巴西镰状细胞贫血患者临床严重程度

A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.
PubMed 文献 · Br J Haematol · 2026-04-16

该研究在409例巴西成人镰状细胞贫血患者中,分析BCL11A四个单核苷酸多态性(SNP)和HBS1L-MYB rs9399137与胎儿血红蛋白(HbF)水平及临床并发症的关联。结果显示所有SNP变异等位基因均与较高HbF水平相关,而主要等位基因纯合与卒中、股骨头坏死等并发症风险增加独立相关;整合遗传风险评分(GRS)与临床变量的模型曲线下面积(AUC)为0.72,优于仅用临床因素的模型。

要点

  • BCL11A和HBS1L-MYB变异等位基因与较高HbF水平相关。
  • 主要等位基因纯合与卒中、股骨头坏死等并发症风险增加独立相关。
  • GRS与较低HbF水平及较高并发症风险显著相关,整合模型AUC为0.72。

核心结论

  • HbF相关遗传变异具有临床相关性,支持将其纳入镰状细胞贫血的风险分层和个体化管理策略。

研究设计与样本

  • 研究纳入409例巴西成人镰状细胞贫血患者,分析BCL11A rs4671393、rs1427407、rs11886868和HBS1L-MYB rs9399137多态性与HbF水平及临床并发症的关联。

主要发现

  • 所有四个SNP的变异等位基因均与较高HbF水平显著相关。
  • 主要等位基因纯合与卒中、股骨头坏死、腿部溃疡、异常勃起和急性胸部综合征的更高风险和累积发病率独立相关。
  • BCL11A变异单倍型分析与HbF水平及患者表型相关。
  • 结合风险基因型的GRS与较低HbF水平(p < 0.0001)和增加并发症风险(p < 0.0001)显著相关。
  • 整合GRS与临床变量的模型 discriminatory performance(AUC:0.72)优于仅基于临床因素的模型。

临床怎么用

  • 可考虑将HbF相关遗传变异(如BCL11A和HBS1L-MYB)纳入镰状细胞贫血患者的风险分层。
  • GRS结合临床变量可能有助于识别并发症高风险患者,指导个体化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals with sickle cell anaemia (SCA) exhibit significant clinical heterogeneity influenced by several factors, especially fetal haemoglobin (HbF) levels. Variations in adult HbF levels are partly explained by the co-inheritance of genetic variants that regulate globin expression. In this study, we investigated the association of BCL11A rs4671393, rs1427407, rs11886868 and HBS1L-MYB rs9399137 polymorphisms with HbF levels and clinical complications in a cohort of 409 adult Brazilian SCA patients. Our findings reveal that variant alleles of all four single-nucleotide polymorphisms (SNPs) were significantly associated with higher HbF levels. Moreover, homozygosity for the major alleles was independently associated with higher risk and cumulative incidence of stroke, avascular necrosis, leg ulcers, priapism and acute chest syndrome. Haplotype analysis with BCL11A variants was also associated with HbF and the patient's phenotype. A genetic risk score (GRS) combining the risk genotypes was significantly associated with lower HbF levels (p < 0.0001) and increased complication risk (p < 0.0001). A model integrating the GRS with clinical variables demonstrated superior discriminatory performance (area under the curve (AUC): 0.72) compared to models based solely on clinical factors. In summary, this study underscores the clinical relevance of HbF-related genetic variants and supports their integration into risk stratification and personalized management strategies for SCA.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Arcanjo GS, Silva AP, Diniz MV, et al. A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients. Br J Haematol. 2026. PMID: 41989145. doi:10.1111/bjh.70489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。